|
|
Randomized Study of Electroacupuncture for Treatment of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Newly Diagnosed Pediatric Sarcoma, Neuroblastoma, Nasopharyngeal Carcinoma, Germ Cell Tumors, or Hodgkin Lymphoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Supportive care
|
|
|
|
Active
|
|
|
|
5 to 35
|
|
|
|
NCCAM, NCI
|
|
|
|
NCCAM-02-AT-0172 NCI-02-AT-0172, COG-ACCL04C2, ACCL04C2, NCT00040911
|
|
|
Special Category:
NIH Clinical Center trial Objectives Primary - Determine the efficacy of electroacupuncture, in terms of reducing acute and delayed chemotherapy-induced nausea, in patients with newly diagnosed pediatric sarcoma, neuroblastoma, nasopharyngeal carcinoma, or germ cell tumors.
Secondary - Determine the efficacy of this therapy, in terms of reducing delayed chemotherapy-induced emesis, in these patients.
- Determine the efficacy of this therapy, in terms of altering salivary cortisol levels and fasting serum glucose and insulin levels as stress parameters, in these patients.
- Determine the efficacy of this therapy, in terms of improving the quality of life, in these patients.
- Determine the efficacy of this therapy, in terms of reducing acute nausea and emesis, in these patients.
Entry Criteria Disease Characteristics:
- Newly diagnosed malignancy of 1 of the following types:
- Pediatric sarcoma
- Neuroblastoma
- Nasopharyngeal carcinoma
- Germ cell tumor
- Hodgkin lymphoma
- Meets 1 of the following criteria:
- Eligible for Children's Oncology Group (COG) protocol for sarcoma, neuroblastoma, or germ cell tumor
- Eligible for NCI Pediatric Oncology Branch (POB) protocol for sarcoma
- Following COG-approved standard treatment regimen for sarcoma, neuroblastoma, nasopharyngeal carcinoma, or germ cell tumor
- Enrolled on the POB natural history protocol 98-C-0037
- Planned treatment, according to COG or POB protocols, that includes a cisplatin- and/or doxorubicin-containing regimen for sarcoma, neuroblastoma, nasopharyngeal carcinoma, germ cell tumor, or Hodgkin lymphoma OR either a cyclophosphamide/ifosfamide-doxorubicin-containing or cyclophosphamide/dactinomycin-containing regimen for rhabdomyosarcoma
- No clinical or radiographic signs of spinal cord compression
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: - See Disease Characteristics
- No prior systemic chemotherapy
Endocrine therapy: - More than 4 weeks since prior glucocorticoid therapy
- No concurrent glucocorticoid therapy
Radiotherapy: Surgery: Other: - No prior acupuncture
- No concurrent anticoagulants
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Platelet count greater than 50,000/mm3 (transfusion
independent)
- No clotting disorders, including hemophilia
Hepatic: - PT and PTT normal (within 10% of institution's upper limit of normal)
Renal: Other: - Not pregnant
- No casting of 1 or more extremities
- No other condition that would preclude access to acupuncture
points
- No cognitive impairment
Expected Enrollment 65A total of 65 patients (approximately 32 per arm) will be accrued for this study within
2.5-3 years. Outcomes Primary Outcome(s)Delayed nausea by Marrow Assessment of Nausea and Emesis at 1, 3, and 6 weeks after study completion
Secondary Outcome(s)Quality of life by QLQ C-30 at 1, 3, and 6 weeks after study completion
Pain by Brief Pain Inventory at 1, 3, and 6 weeks after study completion
Outline This is a multicenter, randomized, double-blind study. Patients are stratified
according to planned treatment with cisplatin-based chemotherapy (yes vs no) and gender. Patients are randomized to 1 of 2
arms. - Arm I: Patients undergo electroacupuncture to specific acupuncture
points on the arms and legs over 25 minutes twice daily on days 1 and 2 and
then once daily on days 3-7 during week 1 of chemotherapy course 1 (9 acupuncture treatments total).
- Arm II: Patients undergo electroacupuncture to sham points on the arms
and legs as in arm I.
Quality of life is assessed at baseline, on days 1 and 8 of each
treatment course, and then after completion of the study.
Trial Contact Information
Trial Lead Organizations National Center for Complementary and Alternative Medicine | | | Patrick Mansky, MD, Principal investigator | | | |
Children's Oncology Group | | | Kara Kelly, MD, Protocol chair | | | | Trial Sites
|
|
|
|
U.S.A. |
|
California |
|
|
Madera |
|
| | | | Children's Hospital Central California |
| | Vonda Crouse | |
|
Georgia |
|
|
Atlanta |
|
| | | Winship Cancer Institute of Emory University |
| | Howard Katzenstein | |
|
Maryland |
|
|
Bethesda |
|
| | | Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office |
| | Clinical Trials Office - Warren Grant Magnusen Clinical Center - NCI Clinical Trials Referral Office | |
|
Minnesota |
|
|
Minneapolis |
|
| | | Children's Hospitals and Clinics of Minnesota - Minneapolis |
| | Clinical Trials Office - Children's Hospitals and Clinics of Minnesota | |
|
New York |
|
|
New York |
|
| | | Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center |
| | Clinical Trials Office - Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center | |
|
|
Syracuse |
|
| | SUNY Upstate Medical University Hospital |
| | Clinical Trials Office - SUNY Upstate Medical University Hospital | |
|
Ohio |
|
|
Cincinnati |
|
| | | Cincinnati Children's Hospital Medical Center |
| | Clinical Trials Office - Cincinnati Children's Hospital Medical Center | |
|
Oklahoma |
|
|
Tulsa |
|
| | | Natalie Warren Bryant Cancer Center at St. Francis Hospital |
| | Gregory Kirkpatrick | |
|
Oregon |
|
|
Portland |
|
| | | Legacy Emanuel Hospital and Health Center and Children's Hospital |
| | Clinical Trials Office - Legacy Emanuel Hospital and Health Center and Children's Hospital | |
|
South Carolina |
|
|
Charleston |
|
| | | Hollings Cancer Center at Medical University of South Carolina |
| | Clinical Trials Office - Hollings Cancer Center at Medical University of South Carolina | |
|
Washington |
|
|
Seattle |
|
| | | Children's Hospital and Regional Medical Center - Seattle |
| | Douglas Hawkins | |
|
|
Spokane |
|
| | Providence Cancer Center at Sacred Heart Medical Center |
| | Judy Felgenhauer | |
|
Canada |
|
Nova Scotia |
|
|
Halifax |
|
| | | | IWK Health Centre |
| | Margaret Yhap | |
|
Registry Information | | Official Title | | A Randomized Study Of Electroacupuncture Treatment For Delayed Chemotherapy-Induced Nausea And Vomiting In Patients With Pediatric Solid Tumors | | Trial Start Date | | 2002-04-24 | | Trial Completion Date | | 2008-12-31 (estimated) | | Registered in ClinicalTrials.gov | | NCT00040911 | | Date Submitted to PDQ | | 2002-05-07 | | Information Last Verified | | 2008-10-02 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|